 STUDY OF AN EXTENDED-RELEASE, CRYSTALLINE FORMULATION OF RECOMBINANT HUMAN GROWTH HORMONE ALTU-238 IN GROWTH HORMONE DEFICIENT ADULTS TO DETERMINE PHARMACOKINETICS, PHARMACODYNAMICS, AND DRUG SAFETY: 